我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
12
6 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
5
41.7%
已完成
Enrolling By Invitation
1
8.3%
招募中
暂无批准数据
• The STAR-GLOBAL trial demonstrated MINIject maintained a significant 38% reduction in intraocular pressure through five years, with 83% of patients achieving >20% IOP reduction from baseline. • Over 5,000 patients worldwide have received the supraciliary MIGS device since its commercial launch, with data confirming a favorable long-term safety profile including corneal health. • iSTAR Medical will continue independent development of MINIject following the conclusion of its partnership with AbbVie, with FDA submission targeted for 2028.
